非吸烟女性肺腺癌组织中 miRNAs 的表达与表皮生长因子受体关系的研究

目的 探讨非吸烟女性肺腺癌(ADC)组织中 miR-155、miR-16、miR-25 及 miR-133a 的表达与表皮生长因子受体（EGFR）的关系及其临床意义。 方法 112 例非吸烟女性 ADC 患者按 EGFR 类型分为 EGFR 野生型组（n= 51）和 EGFR 突变型组（n=61）。 用实时荧光定量 PCR 定量检测 2 组 ADC 组织中 4 种 miRNAs 的表达量， 比较 2 组 4 种 miRNAs 表达水平的差异。 4 种 miRNAs 表达量以平均数分层为高表达组和低表达组， 比较 2 亚组患者间的生存差异。 按年龄（≤60 岁， ＞ 60 岁）、EGFR 类型和 miRNAs 的表达量分层， 进行 Kaplan-Meier 生存分析和 Cox 比例风险回归模型检验。 结果 EGFR 突变型组 miR-25 的表达水平高于 EGFR 野生型组（P < 0.05）。 不同年龄分层、不同 EGFR 类型组、miR-155、miR-16 及 miR-133a 表达量患者的生存率差异无统计学意义， miR-25 低表达者的生存率较高表达者更高（P < 0.05）。 在 EGFR 突变型组中 4 种 miRNAs 的表达量与 ADC 预后无关（P > 0.05）； 在 EGFR 野生型组中 miR-16、miR-25、miR-133a 低表达者较高表达者生存率更高（P < 0.05）。 Cox 比例风险回归分析显示， miR-25 高表达是非吸烟女性 ADC 患者预后死亡的独立危险因素（P < 0.05）。 结论 miR-25 是非吸烟女性 ADC 的独立预后指标。 miR-25 在非吸烟女性 ADC， 特别是在 EGFR 野生型的患者中表达升高， 可能提示患者预后不佳。

Study on the relationship between expression of miRNAs and receptors of epidermal growth factor in lung adenocarcinoma of non-smoking female

Objective To determine association between the expression of miR-155, miR-16, miR-25 and miR-133 and epidermal growth factor receptor (EGFR) in lung adenocarcinoma (ADC) samples of non-smoking female, and their clini? cal significance thereof. Methods According to EGFR types, 112 non-smoking female ADC patients were divided into two groups: EGFR wild (n=51) and EGFR mutant (n=61) groups. Expression levels of four miRNAs were detected by real time quantitative PCR. T-test was used to compare differences of four miRNAs expression in two groups. ADC patients were divid? ed into high miRNA expression group and low expression group according to the mean value of miRNAs expression. Logrank test was used to compare the survival difference between the two subgroups. Cox proportional hazards regression analy? sis was performed to determine the association between different ages (≤60， >60), EGFR types, miRNAs expression and over? all survival. Results The expression of miR-25 was significantly higher in EGFR mutant group than that in EGFR wild group (P < 0.05). There were no significant differences in the survival rates of patients with different ages, EGFR types, and the expressions of miR-155, miR-16 and miR-133a. Patients with the lower expression of miR-25 had the higher survival time than patients with the higher expression of miR-25 (P < 0.05). In EGFR mutation group, there was no relationship be? tween four miRNAs and the prognosis of ADC (P > 0.05). In EGFR wild group, the lower expression of miR-16, miR-25 or miR-133a was associated with longer survival in ADC (P < 0.05). Cox proportional hazards regression analysis revealed that the high expression of miR-25 was an independent risk factor for non-smoking female patients with ADC (P < 0.05). Con? clusion miR-25 is an independent prognostic indicator for non-smoking female patients with ADC. High expression of miR-25 is found in non-smoking female patients with ADC, particularly in patients with EGFR wild-type, which may sug? gest a poor prognosis.